CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that the underwriters of its initial public offering (IPO) exercised in full their option to purchase from SAGE 750,000 additional shares of its common stock at the IPO price of $18.00 per share.
Help employers find you! Check out all the jobs and post your resume.
